Symbols

ALLO

Allogene·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 3

Consensus Rating "Sell"

Ample Liquidity

Significant Revenue Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ALLO

Allogene Therapeutics, Inc.

A company that developing genetically engineered allogeneic T cell therapies for cancer

Industry

Biological Technology

Established Date

11/30/2017

Listing Date

10/11/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

226

Fiscal Year Ends

12-31

Website

www.allogene.com

Security Type

Common stock

Office address

210 East Grand Avenue, South San Francisco, California 94080

Business

Introduction

Allogene Therapeutics, Inc., was incorporated in Delaware on November 30, 2017 and is headquartered in South San Francisco, California. The company is a clinical-stage immuno-oncology company that has pioneered the development and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of cancer. The Company is developing a line of off-the-shelf T cell product candidates designed to target and kill cancer cells. Allogene Therapeutics, Inc .'s engineered T cells are allogeneic, which means that they come from a healthy donor and are used in any patient, not in the case of an individual patient from a patient, such as autologous T cells.

Earnings Call

Q1/2025

Estimate EPS-0.29

Actual EPS-0.28

Estimate Revenue1.67K

Actual Revenue0

Allogene Therapeutics Q1 2025: Navigating Contradictions in ALPHA3 Enrollment and ALLO-329 Strategies

May 20,2025 12:31·
Earnings Decrypt

Q2/2025

Estimate EPS-0.26

Actual EPS-0.23

Estimate Revenue--

Actual Revenue0

ALPHA3 Trial Update: Contradictions in Enrollment, Data Expectations, and Lymphodepletion Strategies

Aug 13,2025 09:56·
Earnings Decrypt

Company Financials

EPS

ALLO has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.23, beating expectations. The chart below visualizes how ALLO has performed over recent quarters, highlighting trends in earnings surprises.